NovoCure Limited(NVCR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVCR NovoCure Limited

盘前交易 07-08 08:02:57 EDT

17.72

+0.40

+2.31%

盘前17.62

-0.10-0.57%

04:00 EDT

最高17.76	最低16.64	成交量105.78万
今开17.13	昨收17.32	日振幅6.47%
总市值20.52亿	流通市值16.88亿	总股本1.16亿
成交额1,846万	换手率1.11%	流通股本9,525万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVCR","market":"US","secType":"STK","nameCN":"NovoCure Limited","latestPrice":17.72,"timestamp":1783454400000,"preClose":17.32,"halted":0,"volume":1057795,"hourTrading":{"tag":"盘前","latestPrice":17.619,"preClose":17.72,"latestTime":"04:00 EDT","volume":3,"amount":53.44799999999999,"timestamp":1783497619685,"change":-0.101,"changeRate":-0.0057,"amplitude":0},"delay":0,"changeRate":0.023094688221708924,"floatShares":95248300,"shares":115820940,"eps":-1.539021,"marketStatus":"盘前交易","change":0.4,"latestTime":"07-08 08:02:57 EDT","open":17.13,"high":17.76,"low":16.64,"amount":18457999.141475,"amplitude":0.064665,"askPrice":19.34,"askSize":100,"bidPrice":15.98,"bidSize":114,"shortable":3,"etf":0,"ttmEps":-1.539021,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783517400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1443758400000,"exchange":"NASDAQ","adjPreClose":17.72,"preHourTrading":{"tag":"盘前","latestPrice":17.619,"preClose":17.72,"latestTime":"04:00 EDT","volume":3,"amount":53.44799999999999,"timestamp":1783497619685,"change":-0.101,"changeRate":-0.0057,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":17.72,"preClose":17.72,"latestTime":"17:41 EDT","volume":17337,"amount":307214.22,"timestamp":1783460518086,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7019277423799002,"impliedVol":0.5144,"impliedVolPercentile":0.132},"requestUrl":"/m/hq/s/NVCR","defaultTab":"news","newsList":[{"id":"1171392988","title":"NovoCure试验数据：早期启动组中位总生存期17.7个月，维持启动组为17.5个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1171392988","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171392988?lang=zh_cn&edition=full","pubTime":"2026-06-18 19:04","pubTimestamp":1781780665,"startTime":"0","endTime":"0","summary":"NovoCure Limited公布的最新临床试验数据显示，其肿瘤治疗电场疗法在针对特定脑癌患者的试验中取得了积极进展。在关键的总生存期指标上，接受早期干预的患者组（Early Start Arm）中位总生存期达到17.7个月，而对照的维持启动组（Maintenance Start Arm）则为17.5个月。两组数据均显示出该疗法在延长患者生存时间方面的潜力，早期干预组略占优势。\n这一结果对于评估该创新疗法的临床价值具有重要参考意义。尽管两组间差异不大，但数据进一步证实了肿瘤治疗电场疗法作为现有标准治疗方案补充的可行性。公司将继续推进相关临床研究，以获取更全面的疗效与安全性数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","NVCR","BK4082","BK4585","BK4534","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179497465","title":"NovoCure公布三期Trident试验顶线数据，评估肿瘤电场疗法在初诊胶质母细胞瘤中的早期应用","url":"https://stock-news.laohu8.com/highlight/detail?id=1179497465","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179497465?lang=zh_cn&edition=full","pubTime":"2026-06-18 19:01","pubTimestamp":1781780476,"startTime":"0","endTime":"0","summary":"NovoCure Limited公布了其关键三期Trident试验的顶线结果。该研究旨在评估肿瘤电场疗法在初诊胶质母细胞瘤患者中更早介入的疗效与安全性。\n胶质母细胞瘤是一种极具侵袭性的脑癌，治疗选择有限。肿瘤电场疗法是一种利用特定频率电场干扰癌细胞分裂的物理疗法。Trident试验探索了在标准治疗方案（包括手术、放疗和化疗）基础上，于更早阶段联合使用该疗法是否能带来更佳的临床获益。\n此次公布的顶线数据为后续的详细分析和在学术会议及同行评审期刊上的完整结果发布奠定了基础。公司表示，这些数据将用于支持与全球监管机构的沟通，以探讨该疗法在更广泛患者群体中应用的潜在路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4588","BK4534","BK4548","NVCR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179260354","title":"异动解读 | NovoCure Limited盘中大涨25.78%，因Q1营收超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1179260354","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179260354?lang=zh_cn&edition=full","pubTime":"2026-04-30 21:46","pubTimestamp":1777556809,"startTime":"0","endTime":"0","summary":"肿瘤治疗技术公司NovoCure Limited（股票代码：NVCR）今日盘中股价大幅上涨25.78%，引起了市场的广泛关注。消息面上，公司公布了第一季度财务业绩，其营收表现超出市场预期。报告显示，该公司第一季度营收达到1.74055亿美元，显著高于市场研究机构IBES此前预估的1.679亿美元。这一积极的业绩数据提振了投资者信心，成为推动股价上涨的主要因素。不过，相关报告也指出，公司在营收向好的同时，盈利能力仍面临挑战，第一季度运营收入为亏损6742万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171501544","title":"异动解读 | NovoCure Limited盘前大涨13.08%，因Q1营收超市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1171501544","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171501544?lang=zh_cn&edition=full","pubTime":"2026-04-30 19:30","pubTimestamp":1777548628,"startTime":"0","endTime":"0","summary":"肿瘤治疗技术公司NovoCure Limited（股票代码：NVCR）今日盘前股价大幅上涨13.08%，引起了市场的广泛关注。消息面上，公司公布了第一季度财务业绩，其营收表现超出市场预期。报告显示，该公司第一季度营收达到1.74055亿美元，显著高于市场研究机构IBES此前预估的1.679亿美元。这一积极的业绩数据提振了投资者信心，成为推动股价上涨的主要因素。不过，相关报告也指出，公司在营收向好的同时，盈利能力仍面临挑战，第一季度运营收入为亏损6742万美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107165005","title":"Novocure Q1营收1.74亿美元超预期，但运营亏损6742万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1107165005","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107165005?lang=zh_cn&edition=full","pubTime":"2026-04-30 19:13","pubTimestamp":1777547631,"startTime":"0","endTime":"0","summary":"肿瘤治疗技术公司NovoCure Limited公布第一季度财务业绩，其营收表现超出市场预期。报告显示，该公司第一季度营收达到1.74055亿美元，显著高于市场研究机构IBES此前预估的1.679亿美元。\n然而，在营收向好的同时，公司盈利能力仍面临挑战。第一季度运营收入为亏损6742万美元，凸显出公司在控制成本和提高运营效率方面仍有改进空间。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4534","NVCR","BK4585","BK4082","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187637909","title":"财报前瞻｜NovoCure Limited本季度营收预计增14.50%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1187637909","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187637909?lang=zh_cn&edition=full","pubTime":"2026-04-23 15:28","pubTimestamp":1776929280,"startTime":"0","endTime":"0","summary":"NovoCure Limited将于2026年04月30日盘前发布财报，市场共识聚焦营收回升与亏损幅度变化及新适应症放量节奏。市场一致预期本季度NovoCure Limited营收约为美元1.68亿，同比增长14.50%；调整后每股收益预计为-0.51，同比下降10.46%；息税前利润预计为亏损美元5,498.20万，同比下降7.09%；目前未见公司层面披露的本季度毛利率与净利润或净利率指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜NovoCure Limited本季度营收预计增14.50%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1154160879","title":"财报前瞻｜NovoCure Limited本季度营收预计增14.50%，机构观点偏看多","url":"https://stock-news.laohu8.com/highlight/detail?id=1154160879","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154160879?lang=zh_cn&edition=full","pubTime":"2026-04-13 08:27","pubTimestamp":1776040026,"startTime":"0","endTime":"0","summary":"NovoCure Limited预计将于2026年04月20日发布财报，市场聚焦胰腺癌新适应症落地后的放量节奏与利润路径变化。检索期内，围绕NovoCure Limited的公开信息多为正面：公司在2026年02月宣布Optune Pax获美国监管批准用于胰腺癌，随后在2026年03月披露日本对Optune Lua给予医保支付支持，同时2026年02月季度财报口径显示营收与EPS均小幅优于市场一致预期，股价在相关公告时段多次出现盘前上行。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜NovoCure Limited本季度营收预计增14.50%，机构观点偏看多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100329660","title":"Novocure公布肿瘤电场疗法治疗转移性胰腺癌的2期Panova-4临床试验积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1100329660","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100329660?lang=zh_cn&edition=full","pubTime":"2026-03-26 19:05","pubTimestamp":1774523142,"startTime":"0","endTime":"0","summary":"Novocure Limited（纳斯达克代码：NVCR）近日宣布，其针对转移性胰腺癌的肿瘤电场疗法（TtFields）在2期Panova-4临床试验中取得了积极的顶线结果。该研究达到了其主要终点，显示出令人鼓舞的疗效信号和可控的安全性特征。\n这一突破性进展为罹患这种侵袭性癌症的患者带来了新的希望。肿瘤电场疗法是一种利用特定频率电场干扰癌细胞分裂的局部治疗方式。胰腺癌因其诊断晚、治疗选择有限且预后差，一直是肿瘤学领域的重大挑战。\nPanova-4试验的成功结果有望为后续的关键性临床研究奠定坚实基础，并进一步拓展肿瘤电场疗法在实体瘤治疗中的应用边界。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR","BK4082","BK4588","BK4548","BK4585","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117552504","title":"Novocure宣布Optune Lua®在日本获得用于治疗非小细胞肺癌的报销批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1117552504","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117552504?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:11","pubTimestamp":1772453470,"startTime":"0","endTime":"0","summary":"Novocure Limited（纳斯达克代码：NVCR）近日宣布，其创新产品Optune Lua®已获得日本监管机构的报销批准，可用于治疗非小细胞肺癌（NSCLC）。这一重要里程碑意味着，符合条件的日本非小细胞肺癌患者将能够获得该疗法的保险覆盖，从而减轻治疗的经济负担。\nOptune Lua®是一种采用肿瘤治疗电场（TTFields）技术的非侵入性癌症疗法。此次报销批准有望提升该疗法在日本的可及性，为更多患者提供一种新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR","BK4548","BK4534","BK4588","BK4082","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116793722","title":"Novocure Q4营收1.7435亿美元，超出IBES预期1.734亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1116793722","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116793722?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:24","pubTimestamp":1772108658,"startTime":"0","endTime":"0","summary":"Novocure第四季度实现毛利润1.32193亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","NVCR","BK4082","BK4588","BK4534","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143614733","title":"财报前瞻 ｜NovoCure Limited本季度营收预计增长9.85%，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1143614733","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143614733?lang=zh_cn&edition=full","pubTime":"2026-02-19 14:38","pubTimestamp":1771483128,"startTime":"0","endTime":"0","summary":"NovoCure Limited将于2026年02月26日发布最新季度财报，市场围绕核心产品商业化进展与利润率修复展开讨论。市场一致预期显示，本季度营收预计为1.73亿美元，同比增长9.85%；调整后每股收益预计为-0.41美元，同比下降19.65%；息税前利润预计为-4,314.55万美元，同比下降4.30%。公司未在上季度财报中明确披露本季度毛利率与净利率的具体预测。分业务来看，核心TTFields相关产品与服务为主营，收入为1.67亿美元，同比增长7.81%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 ｜NovoCure Limited本季度营收预计增长9.85%，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182968803","title":"异动解读 | FDA批准胰腺癌治疗设备，NovoCure盘中大涨40.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=1182968803","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182968803?lang=zh_cn&edition=full","pubTime":"2026-02-12 22:51","pubTimestamp":1770907861,"startTime":"0","endTime":"0","summary":"NovoCure Limited（NVCR）今日盘中大涨40.48%，引起了市场的广泛关注。消息面上，美国食品药品监督管理局（FDA）已正式批准NovoCure Limited研发的Optune Pax设备上市。该设备是全球首款专门用于治疗局部晚期胰腺癌成人患者的创新医疗器械，标志着胰腺癌治疗领域取得重大突破。这一重要监管进展为胰腺癌患者提供了全新的治疗选择，有望改善现有治疗格局，并推动公司商业化进程，从而增强了投资者对公司未来增长潜力的信心。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139847202","title":"FDA批准NovoCure的Optune Pax：全球首款用于局部晚期胰腺癌成人患者的创新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1139847202","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139847202?lang=zh_cn&edition=full","pubTime":"2026-02-12 21:52","pubTimestamp":1770904334,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准NovoCure Limited（NASDAQ: NVCR）研发的Optune Pax设备上市。该设备是全球首款专门用于治疗局部晚期胰腺癌成人患者的创新医疗器械，标志着胰腺癌治疗领域取得重大突破。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4548","BK4082","NVCR","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110129122","title":"异动解读 | FDA批准胰腺癌治疗设备，NovoCure盘前大涨26.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110129122","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110129122?lang=zh_cn&edition=full","pubTime":"2026-02-12 17:46","pubTimestamp":1770889617,"startTime":"0","endTime":"0","summary":"NovoCure Limited今日盘前股价大幅上涨26.67%，引起了市场的广泛关注。消息面上，美国食品药品监督管理局已正式批准NovoCure Limited旗下肿瘤治疗设备Optune Pax用于局部晚期胰腺癌的治疗方案。根据公司公开信息，Optune Pax作为非侵入性肿瘤治疗系统，通过交替电场技术抑制癌细胞分裂。该批准基于III期临床研究数据，结果显示结合标准化疗方案使用时，Optune Pax能显著提升患者生存期。公司表示将立即启动商业化进程，确保医疗专业人员能够及时获取该创新治疗设备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194231127","title":"NovoCure Limited：FDA批准Optune Pax用于局部晚期胰腺癌治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1194231127","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1194231127?lang=zh_cn&edition=full","pubTime":"2026-02-12 06:31","pubTimestamp":1770849076,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式批准NovoCure Limited旗下肿瘤治疗设备Optune Pax用于局部晚期胰腺癌的治疗方案。这一重要监管进展标志着该创新疗法在临床应用领域取得关键突破。\n根据公司向美国证券交易委员会提交的公开文件，Optune Pax作为非侵入性肿瘤治疗系统，将通过交替电场技术抑制癌细胞分裂。此次获批为胰腺癌患者提供了全新的治疗选择，有望改善现有治疗格局。\n该批准基于III期临床研究数据，结果显示结合标准化疗方案使用时，Optune Pax能显著提升患者生存期。公司表示将立即启动商业化进程，确保医疗专业人员能够及时获取该创新治疗设备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4585","NVCR","BK4588","BK4548","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153953369","title":"NovoCure公布2025财年及第四季度初步业绩，并更新公司动态","url":"https://stock-news.laohu8.com/highlight/detail?id=1153953369","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153953369?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:07","pubTimestamp":1768219634,"startTime":"0","endTime":"0","summary":"NovoCure Limited (NVCR) 近日披露了2025财年全年及第四季度的初步运营数据，同时向市场通报了公司最新的发展进展。此次公布旨在让投资者及时了解公司在财务表现和战略推进方面的关键信息。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4585","NVCR","BK4534","BK4588","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102095631","title":"NovoCure将继续按产品（Optune Gio、Optune Lua）和重点市场细分报告在治患者数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1102095631","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102095631?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:05","pubTimestamp":1768219518,"startTime":"0","endTime":"0","summary":"NovoCure Limited宣布，未来将持续公布其治疗设备在临床应用中活跃患者的具体分布情况。相关数据将按两大核心维度进行细化分类：一是根据产品类型划分，包括Optune Gio与Optune Lua两种治疗方案；二是依据不同区域的重点市场进行统计。这一举措旨在提升治疗进展的透明度，帮助投资者更精准地评估各产品线及区域市场的临床渗透率与增长动能。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","NVCR","BK4548","BK4588","BK4534","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182636208","title":"NovoCure Limited计划自2026年第一季度起停止报告上市超过一年的适应症新处方数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1182636208","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182636208?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:04","pubTimestamp":1768219476,"startTime":"0","endTime":"0","summary":"医疗技术公司NovoCure Limited近日宣布，公司计划从2026年第一季度开始，调整其业务数据披露策略。具体而言，NovoCure将不再定期公布那些已上市超过一年的适应症所获得的新处方数量。随着其肿瘤电场疗法在更多市场获批并应用日益成熟，部分适应症的处方增长已趋于稳定。因此，公司认为继续单独披露这些成熟适应症的新处方数据，其信息增量和对投资者的参考价值相对有限。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4548","BK4082","NVCR","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517162511","title":"Novocure Limited2024财年实现净利润-1.69亿美元，同比增加18.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517162511","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517162511?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:01","pubTimestamp":1741276872,"startTime":"0","endTime":"0","summary":"3月7日，Novocure Limited公布财报，公告显示公司2024财年净利润为-1.69亿美元，同比增加18.36%；其中营业收入为6.05亿美元，同比增加18.86%，每股基本收益为-1.56美元。从资产负债表来看，Novocure Limited总负债8.81亿美元，其中短期债务5.66亿美元，资产负债比为1.41，流动比率为1.47。机构评级：截至2025年3月7日，当前有7家机构对Novocure Limited目标价做出预测，其中目标均价为35.57美元，其中最低目标价为29.00美元，最高目标价为42.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000141a262a624&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000141a262a624&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517237919","title":"Novocure Limited盘中异动 下午盘股价大涨5.06%报19.11美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517237919","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517237919?lang=zh_cn&edition=full","pubTime":"2025-03-06 03:08","pubTimestamp":1741201686,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日03时08分，Novocure Limited股票出现波动，股价快速拉升5.06%。截至发稿，该股报19.11美元/股，成交量47.8953万股，换手率0.44%，振幅7.61%。Novocure Limited股票所在的医疗器械行业中，整体涨幅为1.27%。其相关个股中，Xylo Technologies Ltd、Trisalus Life Sciences Inc C/Wts 10/08/28 、Intelligent Bio Solutions Inc.涨幅较大，古特拉、908 Devices Inc.、Tivic Health Systems, Inc.较为活跃，换手率分别为68.84%、30.64%、10.63%，振幅较大的相关个股有Pavmed Inc C/Wts 30/04/2025 Class Z、Ainos, Inc.、Heartsciences Inc.，振幅分别为40.00%、34.75%、23.28%。Novocure Limited公司简介：NovoCure Ltd服务于美国的医疗保健行业。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306030806a2611461&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306030806a2611461&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4548","BK4588","BK4534","BK4082","NVCR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novocure.com","stockEarnings":[{"period":"1week","weight":0.1696},{"period":"1month","weight":0.0326},{"period":"3month","weight":0.6423},{"period":"6month","weight":0.1917},{"period":"1year","weight":0.0491},{"period":"ytd","weight":0.3705}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":0.0138},{"period":"3month","weight":0.1061},{"period":"6month","weight":0.0844},{"period":"1year","weight":0.2047},{"period":"ytd","weight":0.0965}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novocure Limited是一家于2000年2月11日根据海峡群岛泽西岛法律注册成立的公共有限责任公司。它是一家全球肿瘤学公司，开发了一种被称为肿瘤治疗领域（TTFields）的专有平台技术，该技术利用电场杀死癌细胞。NovoCure的关键商业产品包括Optune Gio、Optune Lua和Optune Pax，它们通过医疗设备提供TTFields疗法。该公司的主要重点是推动其产品的商业采用，获得新适应症的监管批准，以及推进旨在提高侵袭性癌症总生存期的临床项目。NovoCure在多个国家销售其产品，其收入的很大一部分来自美国、德国、法国和日本的市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":-0.026321},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.001726},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.034505},{"month":4,"riseRate":0.545455,"avgChangeRate":0.108267},{"month":5,"riseRate":0.818182,"avgChangeRate":0.133305},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.03448},{"month":7,"riseRate":0.545455,"avgChangeRate":0.011236},{"month":8,"riseRate":0.6,"avgChangeRate":0.019977},{"month":9,"riseRate":0.4,"avgChangeRate":-0.021376},{"month":10,"riseRate":0.2,"avgChangeRate":-0.091688},{"month":11,"riseRate":0.636364,"avgChangeRate":0.077306},{"month":12,"riseRate":0.545455,"avgChangeRate":0.065178}],"exchange":"NASDAQ","name":"NovoCure Limited","nameEN":"NovoCure"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NovoCure Limited(NVCR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供NovoCure Limited(NVCR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"NovoCure Limited,NVCR,NovoCure Limited股票,NovoCure Limited股票老虎,NovoCure Limited股票老虎国际,NovoCure Limited行情,NovoCure Limited股票行情,NovoCure Limited股价,NovoCure Limited股市,NovoCure Limited股票价格,NovoCure Limited股票交易,NovoCure Limited股票购买,NovoCure Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NovoCure Limited(NVCR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供NovoCure Limited(NVCR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}